Comparative Pharmacology
Head-to-head clinical analysis: MEPRO ASPIRIN versus VOLTAREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPRO ASPIRIN versus VOLTAREN.
MEPRO-ASPIRIN vs VOLTAREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Diclofenac inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.
Oral: 50-100 mg every 8-12 hours; maximum 150 mg/day. IM: 75 mg once daily for up to 2 days. Topical gel: apply 2-4 g to affected area 4 times daily.
None Documented
None Documented
Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life.
Terminal elimination half-life is approximately 2 hours (range 1.2–2.5 hours) for diclofenac; this short half-life supports multiple daily dosing. The half-life is not significantly altered in renal impairment but may be prolonged in hepatic disease.
Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%).
Approximately 65% of a dose is excreted renally as unchanged drug and glucuronide conjugates, with about 35% eliminated via biliary/fecal routes as metabolites.
Category D/X
Category C
NSAID / Antiplatelet
NSAID